Trulieve Cannabis Q3 Financials Were Down But Stock Price Jumps

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a constituent in the munKNEE American Cannabis MSO Stocks Index, announced its results for the quarter ended September 30, 2022 late last week, as follows:

Third Quarter 2022 Financial Highlights

(The information below compares Q3 2022 with Q2 2022 and all figures are in U.S. dollars.)

  • Revenue: DOWN 5.6%
  • Gross Profit: DOWN 8.7%
    • Gross Profit Margin: DOWN to 56% from 58%
  • Net Income (Loss): DOWN to $(115)M from $(22)M
    • Adj. Net Income (Loss): UP to $4M from $(1)M (excludes $26 million of transaction, acquisition, integration, and other non-recurring charges and $93 million in asset impairments, disposals and discontinued operations
  • Adj. EBITDA: DOWN 10.8% to $99M
    • Adj. EBITDA Margin: DOWN to 33% from 35%
  • Cash on Hand: $114M

Third Quarter Operational Highlights

  • Invested $38 million in capital expenditures which should decline significantly in 2023 following a multi-year investment cycle to support future growth.
  • Expanded market leading retail positions in Arizona, Florida, and West Virginia, with 11 new dispensary openings.
  • Increased utilization at new indoor 750K square foot cultivation facility in Florida.
  • Commenced cultivation operations in Georgia to support production of low THC oil products for retail launch in early 2023.
  • Rolled out customer data platform in Arizona and Pennsylvania while deepening capabilities in Florida.
  • Contributed to the Smart and Safe Florida campaign, which aims to legalize adult use marijuana in Florida through a ballot initiative in November 2024.

Management Commentary

Kim Rivers, Trulieve CEO, said: 

  • "Many states have yet to implement medical or adult use cannabis programs and there is a growing appetite for substantive federal reform. Trulieve has been preparing for this next phase of industry evolution for years,
    • building our regional hub strategy,
    • scaling cutting-edge cultivation and manufacturing capacity,
    • expanding our leading retail platform,
    • investing in data technology
    • and perfecting the customer journey."


Based on our performance year to date and current trends, we are targeting:

  • the low end of 2022 guidance of $1.25 billion to $1.3 billion in revenue
  • and $415 million to $450 million in Adjusted EBITDA.

Stock Performance

Trulieve's stock price declined 26% during Q3 (July, August, and September), but had advanced 27% as of the end of October. The stock price had advanced a further 6% leading up to the release of the Q3 financials after the markets closed on November 9th and then advanced another 9% as of the close of business yesterday. Despite the encouraging advancement in stock price the stock is down 52% YTD.

More By This Author:

Cresco Labs Q3 Financials Show No Improvement Over Q2 Results
Jushi Holdings Releases Mixed Preliminary Q3 Financials
Planet 13 Financial Metrics In Q3 All Declined

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.